DK1272220T3 - Formulering til forebyggelse af kardiovaskulær sygdom - Google Patents
Formulering til forebyggelse af kardiovaskulær sygdomInfo
- Publication number
- DK1272220T3 DK1272220T3 DK01919650T DK01919650T DK1272220T3 DK 1272220 T3 DK1272220 T3 DK 1272220T3 DK 01919650 T DK01919650 T DK 01919650T DK 01919650 T DK01919650 T DK 01919650T DK 1272220 T3 DK1272220 T3 DK 1272220T3
- Authority
- DK
- Denmark
- Prior art keywords
- cardiovascular disease
- formulation
- disease prevention
- prevention
- prevention formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0008791A GB2361185A (en) | 2000-04-10 | 2000-04-10 | Pharmaceutical formulation for the prevention of cardiovascular disease |
GB0100548A GB2361186B (en) | 2000-04-10 | 2001-01-09 | Formulation for the prevention of cardiovascular disease |
PCT/GB2001/001618 WO2001076632A1 (en) | 2000-04-10 | 2001-04-10 | Formulation for the prevention of cardiovascular disease |
Publications (2)
Publication Number | Publication Date |
---|---|
DK1272220T3 true DK1272220T3 (da) | 2006-09-25 |
DK1272220T4 DK1272220T4 (da) | 2016-11-28 |
Family
ID=26244072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01919650.0T DK1272220T4 (da) | 2000-04-10 | 2001-04-10 | Formulering til forebyggelse af kardiovaskulær sygdom |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1272220B2 (da) |
AT (1) | ATE326240T2 (da) |
AU (1) | AU4671101A (da) |
CA (1) | CA2406077C (da) |
CY (1) | CY1105127T1 (da) |
DE (1) | DE60119715T3 (da) |
DK (1) | DK1272220T4 (da) |
ES (1) | ES2263604T5 (da) |
PT (1) | PT1272220E (da) |
WO (1) | WO2001076632A1 (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
DE10222326A1 (de) * | 2002-05-16 | 2003-12-04 | Hexal Ag | Stabile pharmazeutische Formulierung für eine Kombination aus einem Statin mit einem ACE-Hemmer |
BRPI0406987A (pt) | 2003-01-31 | 2006-01-10 | Sankyo Co | Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral |
CN1822820A (zh) | 2003-07-28 | 2006-08-23 | 雷迪实验室有限公司 | 心血管疾病的治疗和预防 |
BRPI0616223A2 (pt) | 2005-09-15 | 2011-06-14 | Otsuka Pharma Co Ltd | combinaÇço de fÁrmacos |
US20070185065A1 (en) * | 2006-02-03 | 2007-08-09 | Vikramjit Chhokar | Combination therapy for coronary artery disease |
ES2300188B1 (es) * | 2006-05-24 | 2009-05-01 | Ferrer Internacional, S.A. | Comprimido bicapa para la prevencion de los accidentes cardiovasculares. |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
CN101590240B (zh) * | 2008-05-30 | 2012-04-25 | 北京奥萨医药研究中心有限公司 | 含血管紧张素ⅱ受体拮抗剂、他汀和叶酸的组合物及用途 |
CN101590239B (zh) * | 2008-05-30 | 2013-03-27 | 北京奥萨医药研究中心有限公司 | 含有利尿剂、他汀和叶酸的药物组合物及其用途 |
EP3239170B1 (en) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
NZ595127A (en) | 2009-02-11 | 2013-08-30 | Cadila Pharmaceuticals Ltd | Stable pharmaceutical composition for atherosclerosis |
US9545446B2 (en) | 2013-02-25 | 2017-01-17 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
DK3573620T3 (da) | 2017-01-25 | 2023-03-20 | The George Inst For Global Health | Sammensætninger til behandling af hypertension |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948443A (en) † | 1996-02-23 | 1999-09-07 | Medical Doctor's Research Institute, Inc. | Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
AU732465B2 (en) * | 1996-04-17 | 2001-04-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
EP0946178A4 (en) * | 1996-09-18 | 2003-05-07 | Merck & Co Inc | COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES |
US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
US6054128A (en) † | 1997-09-29 | 2000-04-25 | Wakat; Diane | Dietary supplements for the cardiovascular system |
-
2001
- 2001-04-10 PT PT01919650T patent/PT1272220E/pt unknown
- 2001-04-10 ES ES01919650.0T patent/ES2263604T5/es not_active Expired - Lifetime
- 2001-04-10 WO PCT/GB2001/001618 patent/WO2001076632A1/en active IP Right Grant
- 2001-04-10 AU AU46711/01A patent/AU4671101A/en not_active Abandoned
- 2001-04-10 AT AT01919650T patent/ATE326240T2/de active
- 2001-04-10 DK DK01919650.0T patent/DK1272220T4/da active
- 2001-04-10 EP EP01919650.0A patent/EP1272220B2/en not_active Expired - Lifetime
- 2001-04-10 DE DE60119715.1T patent/DE60119715T3/de not_active Expired - Lifetime
- 2001-04-10 CA CA2406077A patent/CA2406077C/en not_active Expired - Fee Related
-
2006
- 2006-08-07 CY CY20061101104T patent/CY1105127T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT1272220E (pt) | 2006-10-31 |
DE60119715T2 (de) | 2007-03-15 |
EP1272220A1 (en) | 2003-01-08 |
ES2263604T3 (es) | 2006-12-16 |
ES2263604T5 (es) | 2017-02-07 |
AU4671101A (en) | 2001-10-23 |
EP1272220B2 (en) | 2016-07-27 |
CY1105127T1 (el) | 2009-11-04 |
DE60119715D1 (de) | 2006-06-22 |
EP1272220B1 (en) | 2006-05-17 |
ATE326240T2 (de) | 2006-06-15 |
CA2406077A1 (en) | 2001-10-18 |
DE60119715T3 (de) | 2016-12-08 |
DK1272220T4 (da) | 2016-11-28 |
WO2001076632A1 (en) | 2001-10-18 |
CA2406077C (en) | 2010-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1272220T3 (da) | Formulering til forebyggelse af kardiovaskulær sygdom | |
WO2003000200A3 (en) | β-2'-OR 3'-HALONUCLEOSIDES | |
FI20011851A (fi) | Fluoksetiinia tai sen happoadditiosuolaa sisältävä dispergoituva tabletti | |
DK1283700T3 (da) | Farmaceutiske sustained release-præparater til parenteral administration af biologisk aktive hydrofile forbindelser | |
DK1363608T3 (da) | Formuleringer omfattende ibuprofen og diphenhydramin og deres anvendelse til behandling af sovnforstyrrelser | |
DK1556021T3 (da) | Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger | |
NO20053143L (no) | Farmasoytiske sammensetninger omfattende en basisk, henholdsvis sur legemiddelforbindelse, en sufaktant og en fysiologisk akseptabel vannloselig syre henholdsvis base. | |
MXPA02012937A (es) | Combinaciones de productos activos con propiedades insecticidas y acaricidas. | |
WO2001089457A3 (en) | Thrombopoietin mimetics | |
ATE340844T1 (de) | Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben | |
HUP0401811A2 (hu) | Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására | |
DE60141703D1 (de) | Therapeutische anwendung von zerstäubtem s-nitrosoglutathion bei zystischer fibrose | |
EA200501690A1 (ru) | Композиция, включающая ингибитор pde4 и ингибитор pde5 | |
WO2001072125A3 (de) | Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften | |
WO2002028426A8 (en) | Split enveloped virus preparation | |
WO2003018059A3 (de) | Kombinationspräparate von arylsubstituierten propanolaminderivaten mit weiteren wirkstoffen und deren verwendung | |
BR0212312A (pt) | Clone infeccioso do vìrus da diarréia viral bovina | |
DE60142051D1 (de) | Herstellung von perfluorolefinen | |
WO2004058282A3 (fr) | Procede d’obtention d’un principe actif a partir de mentha piperita presentant des capacites apaisantes | |
ATE335745T1 (de) | Verfahren zur herstellung von protease hemmenden zwischenprodukten | |
HUP0204554A2 (en) | Endoparasiticidal composition, preparation and use thereof | |
ITRM20000494A0 (it) | Varianti di allergeni ns-ltps, loro usi e composizioni che le comprendono. | |
EA200400751A1 (ru) | Применение дезоксипеганина для лечения клинической депрессии | |
WO2002070069A3 (fr) | Utilisation d'un ou plusieurs shogaol(s) en tant qu'aphrodisiaque | |
WO2002002087A3 (de) | Anthelmintika zur verhinderung von parasitären infektionen bei menschen und tieren ii |